Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;18(7):790-802.
doi: 10.1038/ncb3371. Epub 2016 Jun 13.

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity

Affiliations

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity

Caroline Baer et al. Nat Cell Biol. 2016 Jul.

Abstract

Tumour-associated macrophages (TAMs) largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumour-promoting capabilities. Reprogramming TAMs towards a classically activated (M1) phenotype may thwart tumour-associated immunosuppression and unleash anti-tumour immunity. Here we show that conditional deletion of the microRNA (miRNA)-processing enzyme DICER in macrophages prompts M1-like TAM programming, characterized by hyperactive IFN-γ/STAT1 signalling. This rewiring abated the immunosuppressive capacity of TAMs and fostered the recruitment of activated cytotoxic T lymphocytes (CTLs) to the tumours. CTL-derived IFN-γ exacerbated M1 polarization of Dicer1-deficient TAMs and inhibited tumour growth. Remarkably, DICER deficiency in TAMs negated the anti-tumoral effects of macrophage depletion by anti-CSF1R antibodies, and enabled complete tumour eradication by PD1 checkpoint blockade or CD40 agonistic antibodies. Finally, genetic rescue of Let-7 miRNA activity in Dicer1-deficient TAMs partly restored their M2-like phenotype and decreased tumour-infiltrating CTLs. These findings suggest that DICER/Let-7 activity opposes IFN-γ-induced, immunostimulatory M1-like TAM activation, with potential therapeutic implications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109 - PubMed
    1. Nat Genet. 2003 Nov;35(3):215-7 - PubMed
    1. J Immunol. 2010 Jul 1;185(1):400-9 - PubMed
    1. Trends Immunol. 2013 Jul;34(7):350-9 - PubMed
    1. Science. 2008 Apr 4;320(5872):97-100 - PubMed

Publication types